Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in NRT?
Novogen: THE INVESTMENT CASE

Novogen: Access latest PPT from Proactive's CEO Sessions

Dr James Garner talked clinical-stage programs with investors.
Novogen: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: NRT The Big Picture
Dr James Garner, chief executive officer, Novogen

Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April.

Novogen is an emerging oncology drug developer with two clinical-stage programs.

The company's value proposition is to partner with big pharma for late-stage development to bring to market.

ACCESS THE FULL PRESENTATION HERE





Register here to be notified of future NRT Company articles
View full NRT profile View Profile

Novogen Timeline

Newswire
August 05 2015

Related Articles

eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
picture of seeds
July 18 2017
Finncap's revenue forecasts were upgraded by 6% and 7% to £72.2mln and £79.5mln for the full year 2017 and 2018 respectively.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use